A new study investigated the brain circuits involved in psychosis—a condition characterized by delusions, hallucinations, ...

Exposure to amphetamines should be viewed as a stressor in the acute phase for the vulnerable individual in a dynamic way; for individuals with lower vulnerability higher doses of amphetamines are ...

MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, has released enrollment ...

Interestingly, the first English language report on the use of antipsychotic agents in schizophrenia also showed that these drugs have efficacy in the treatment of acute mania, which clinicians ...

A phase 2 randomized, double blind, placebo-controlled, multi-center safety and efficacy trial of brilaroxazine in acute schizophrenia patients—patients who are experiencing severe symptoms ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is the first-ever drug approved for schizophrenia that does not target the D2 ...

Xanomeline/trospium chloride, a novel M1/M4 muscarinic receptor agonist, is linked to significant cognitive improvement in patients with acute schizophrenia and cognitive impairment in pooled data ...

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and ...